All In Biotech

Free tool

FAERS Monitor: Protopam Chloride

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 018799 or its brand name (Protopam Chloride, Pralidoxime Chloride). Reports on generic versions are filed under their own applications.

Reports

26

Serious

15

58% of reports

Hospitalization

10

Death reported

1

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • accidental exposure6
  • expired drug administered5
  • injection site injury4
  • drug ineffective3
  • accidental exposure to product2
  • expired product administered2
  • extrapyramidal disorder2
  • injection site pain2
  • mental disorder due to a general medical condition2
  • peripheral swelling2
  • agitation1
  • agranulocytosis1
  • apnoea1
  • asthma1
  • basal ganglia haemorrhage1

Reports by year received

View as table
YearReports
20102
20114
20122
20134
20144
20151
20172
20192
20201
20213
20241

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,133 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
mental disorder due to a general medical condition25207.61368.85,818
accidental exposureSignal61167.4578.35,867
basal ganglia haemorrhage1996.0145.6248
expired drug administeredSignal5818.1371.93,302
injection site injurySignal4584.0237.01,781
apnoea1103.915.225
extrapyramidal disorder265.217.270
expired product administered248.712.952
agranulocytosis143.56.410
accidental exposure to product215.74.115
agitation111.01.62
peripheral swelling210.52.89
asthma17.21.01
injection site pain25.31.43
drug ineffective31.80.60

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.